

Calendar of Events FY2019

R&D Topics

▶ June

- ONO entered into exclusive license agreement with Rafael Pharmaceuticals on the cancer metabolism inhibitor ONO-7912 (CPI-613) / Devimistat and other related compounds

▶ July

- ONO and Forty Seven signed a license agreement related to the anti-CD47 antibody ONO-7913 / Magrolimab

▶ November

- ONO launched Coralan® Tablets, a HCN channel blocker, for the treatment of chronic heart failure



- ONO received supplemental approval of the proteasome inhibitor KYPROLIS® for Intravenous Injection in Japan for additional dosage and administration for a Kd once-weekly regimen in relapsed or refractory multiple myeloma

2019

4

5

6

7

8

9

ESG Topics

▶ April to June

- After action program of Great East Japan Earthquake reconstruction assistance activity “Operation Slimmer and Healthier in Fukushima” conducted



▶ June

- Medium- and long-term environmental vision for 2050, named “Environment Challenging ONO Vision (ECO VISION 2050)” established
- ONO’s greenhouse gas reduction target approved by the international initiative “Science Based Targets initiative (SBTi)”



SCIENCE
BASED
TARGETS

DRIVING AMBITIOUS CORPORATE CLIMATE ACTION

- Donating teeth-brushing packs and toothbrushes to the elementary schools, kindergartens and nursery centers during the Dental and Oral Health Week

▶ July 2019 to February 2020

- Giving a series of five lessons on the theme of dementia by visiting schools (July, September, December, January and February)

▶ July

- Holding an CSR procurement briefing

▶ September

- Participating in the “Relay For Life” action to fight cancer



R&D

February

- ONO received approval of the anticancer drug OPDIVO (Nivolumab) in Japan for additional indications of unresectable advanced or recurrent esophageal cancer, and MSI-high unresectable advanced or recurrent colorectal cancer
- BMSKK and ONO received approval of the selective T-cell co-stimulation modulator ORENCIA for I.V. Infusion, ORENCIA Syringe for S.C. Injection and ORENCIA Auto-injector for S.C. Injection for a partial change in approved items of the manufacturing and marketing approval in Japan, to include the description of prevention of structural damage of joints in current indication of rheumatoid arthritis

March

- ONO received manufacturing and marketing approval in Japan for the BTK inhibitor VELEXBRU Tablets for treatment of recurrent or refractory primary central nervous system lymphoma
- ONO entered into a new research and option agreement with Numab

2020

10

11

12

1

2

3

● Environment ● Society ● Governance

October

- ONO supported recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)




November

- Adding additional organizations to the donation destination list of "ONO SWITCH Project" (Future Code and People's Hope Japan)
- ONO received "Platinum Kurumin" certification as a company supporting childcare

January

- ONO selected as a "Climate Change A List" Company in CDP 2019 for two consecutive years



October to November

- Science lessons given by the Minase Research institute in October and first by Joto Plant in November on the theme of drugs by visiting schools



December

- ONO received 2019 Environment Minister's Award for Global Warming Prevention Activity in the "Implementation and Dissemination of Countermeasures" category
- Raising for Osaka Marathon charity
- Local subsidiaries joined activities contributing to the local communities

February

- ONO received a certificate of the Whistleblowing Compliance Management System (WCMS)

March

- ONO first selected as a "2020 Health & Productivity Stock"
- Holding an ESG investor meeting

